Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 07:00 ET | Source: Anteris Technologies Global Corp.

FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and...
October 28, 2025 18:08 ET | Source: Anteris Technologies Global Corp.

Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year

Anteris DurAVR THV demonstrates favorable hemodynamics in small annuli patients with no valve related mortality at one year - TCT oral presentation
October 27, 2025 08:43 ET | Source: Anteris Technologies Global Corp.

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed...
September 25, 2025 11:00 ET | Source: EndoQuest Robotics

World’s First Fully Robotic Procedure by a Gastroenterologist Completed Using EndoQuest’s Endoluminal Surgical System in the PARADIGM Trial

Houston, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced the completion of the first procedure...
September 03, 2025 09:00 ET | Source: EndoQuest Robotics

EndoQuest Advances Multicenter PARADIGM Trial with Completion of Procedure at AdventHealth Orlando

Houston, TX, Sept. 03, 2025 (GLOBE NEWSWIRE) -- EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced that AdventHealth Orlando has successfully...